menu search

Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...

February 7, 2022, 10:09 am

Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...

February 7, 2022, 10:09 am

Twist bioscience, eleven therapeutics create synthetic viral rna molecules to develop antiviral vaccines, therapeutics

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral ...

February 7, 2022, 10:09 am

Bionano genomics is interesting as genome testing scales upwards

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....

January 25, 2022, 3:45 pm

Bionano genomics is interesting as genome testing scales upwards

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....

January 25, 2022, 3:45 pm

Bionano genomics is interesting as genome testing scales upwards

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing....

January 25, 2022, 3:45 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm


Search within

Pages Search Results: